Clinical Trial Update: A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia [Phase 1]

View source ↗

Summary

Phase 1 open-label study evaluating pharmacokinetics and safety of aripiprazole IM depot given by deltoid injections in schizophrenia patients; study completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• ARIPIPRAZOLE (Aripiprazole)

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED | Results posted: 2021-01-25